中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2011年
6期
600-603
,共4页
汪小亚%余勤%岳红梅%张佳宾
汪小亞%餘勤%嶽紅梅%張佳賓
왕소아%여근%악홍매%장가빈
慢性阻塞性肺疾病%噻托溴铵%茶碱
慢性阻塞性肺疾病%噻託溴銨%茶堿
만성조새성폐질병%새탁추안%다감
Chronic obstructive pulmonary disease%Tiotropium%Theophylline
目的 评价噻托溴铵联合缓释茶碱治疗中度稳定期慢性阻塞性肺疾病(COPD)的临床疗效及其安全性.方法 将我院2008年3月至2009年12月收治的符合入选标准的80例中度稳定期COPD患者随机分为噻托溴铵组(40例)和噻托溴铵联合缓释茶碱组(40例),分别给予噻托溴铵及噻托溴铵联合缓释茶碱治疗共12周.结果 共70例患者完成试验(噻托溴铵组36例,噻托溴铵联合缓释茶碱组34例),结束时2组患者之间1秒钟用力呼气容积(FEV1)、1秒钟用力呼气容积占预计值百分比(FEV1%)、用力肺活量(FVC)、1秒钟用力呼出气容积占用力肺活量比值(FEV1/FVC)及圣乔治呼吸问卷(SGRQ)活动评分、影响评分等指标差异均无统计学意义(P均>0.05),而噻托溴铵联合缓释茶碱组SGRQ症状评分及总评分较噻托溴铵组明显降低[SGRQ症状评分分别为(53.08±12.25)、(59.39±9.74)分,总评分分别为(23.91±2.57)、(25.27±2.14)分],差异均具有统计学意义(t值分别为2.39,2.40,P均<0.05).40例噻托溴铵组患者发生的与药物相关的不良事件6例:口干4例,心悸1例,便秘1例.40例噻托溴铵联合茶碱组患者发生的与药物相关的不良事件11例:口干3例,胃部不适或恶心3例,腹泻2例,心悸2例,便秘1例,2组患者不良反应差异无统计学意义(P>0.05).结论 噻托溴铵联合缓释茶碱治疗中度稳定期COPD较单用噻托溴铵改善患者症状及生活质量明显,而相关的副作用并无明显增加.
目的 評價噻託溴銨聯閤緩釋茶堿治療中度穩定期慢性阻塞性肺疾病(COPD)的臨床療效及其安全性.方法 將我院2008年3月至2009年12月收治的符閤入選標準的80例中度穩定期COPD患者隨機分為噻託溴銨組(40例)和噻託溴銨聯閤緩釋茶堿組(40例),分彆給予噻託溴銨及噻託溴銨聯閤緩釋茶堿治療共12週.結果 共70例患者完成試驗(噻託溴銨組36例,噻託溴銨聯閤緩釋茶堿組34例),結束時2組患者之間1秒鐘用力呼氣容積(FEV1)、1秒鐘用力呼氣容積佔預計值百分比(FEV1%)、用力肺活量(FVC)、1秒鐘用力呼齣氣容積佔用力肺活量比值(FEV1/FVC)及聖喬治呼吸問捲(SGRQ)活動評分、影響評分等指標差異均無統計學意義(P均>0.05),而噻託溴銨聯閤緩釋茶堿組SGRQ癥狀評分及總評分較噻託溴銨組明顯降低[SGRQ癥狀評分分彆為(53.08±12.25)、(59.39±9.74)分,總評分分彆為(23.91±2.57)、(25.27±2.14)分],差異均具有統計學意義(t值分彆為2.39,2.40,P均<0.05).40例噻託溴銨組患者髮生的與藥物相關的不良事件6例:口榦4例,心悸1例,便祕1例.40例噻託溴銨聯閤茶堿組患者髮生的與藥物相關的不良事件11例:口榦3例,胃部不適或噁心3例,腹瀉2例,心悸2例,便祕1例,2組患者不良反應差異無統計學意義(P>0.05).結論 噻託溴銨聯閤緩釋茶堿治療中度穩定期COPD較單用噻託溴銨改善患者癥狀及生活質量明顯,而相關的副作用併無明顯增加.
목적 평개새탁추안연합완석다감치료중도은정기만성조새성폐질병(COPD)적림상료효급기안전성.방법 장아원2008년3월지2009년12월수치적부합입선표준적80례중도은정기COPD환자수궤분위새탁추안조(40례)화새탁추안연합완석다감조(40례),분별급여새탁추안급새탁추안연합완석다감치료공12주.결과 공70례환자완성시험(새탁추안조36례,새탁추안연합완석다감조34례),결속시2조환자지간1초종용력호기용적(FEV1)、1초종용력호기용적점예계치백분비(FEV1%)、용력폐활량(FVC)、1초종용력호출기용적점용력폐활량비치(FEV1/FVC)급골교치호흡문권(SGRQ)활동평분、영향평분등지표차이균무통계학의의(P균>0.05),이새탁추안연합완석다감조SGRQ증상평분급총평분교새탁추안조명현강저[SGRQ증상평분분별위(53.08±12.25)、(59.39±9.74)분,총평분분별위(23.91±2.57)、(25.27±2.14)분],차이균구유통계학의의(t치분별위2.39,2.40,P균<0.05).40례새탁추안조환자발생적여약물상관적불량사건6례:구간4례,심계1례,편비1례.40례새탁추안연합다감조환자발생적여약물상관적불량사건11례:구간3례,위부불괄혹악심3례,복사2례,심계2례,편비1례,2조환자불량반응차이무통계학의의(P>0.05).결론 새탁추안연합완석다감치료중도은정기COPD교단용새탁추안개선환자증상급생활질량명현,이상관적부작용병무명현증가.
Objective To evaluate the effect and safety of tiotropium plus sustained-release theophylline in treating stable moderate chronic obstructive pulmonary diseases (COPD) . Methods A randomized clinical trail was conducted in 80 patients with stable moderate COPD, who were admitted to our hospital from March 2008 to December 2009. All patients were divided into two groups randomly and accepted tiotropium (groupⅠ ,n =40) or tiotropium plus sustained-release theophylline (group Ⅱ ,n =40) treatment for 12 weeks. Results Seventy patients completed the study,in which 36 cases had tiotropium alone and 34 cases had combination therapy. At the end of treatment, no statistically significant difference was found between the two groups in the comparisons of FEV1, FEV1%, FVC, FEV1/FVC, activity score and impacts score of the St George's Respiratory Questionnaire (SGRQ) (Ps > 0. 05). While the symptoms score (53.08 ± 12.25 vs.59.39±9.74,t=2.39,P<0.05) and total score (23. 91 ±2. 57 vs. 25. 27 ±2.14, t =2.40, P <0.05) of SGRQ were significantly lower in group Ⅱ compared to group Ⅰ. Six adverse events,including dry mouth (n =4), palpitation (re = 1) , constipation (n = 1), were observed in tiotropium alone group during the treatment period. Eleven adverse events were observed in combination treatment group, including dry mouth (re = 3) ,stomach discomfort or nausea (n = 3), diarrhea (re = 2) , palpitation (n = 2), constipation (n = 1) . The incidences of adverse reactions of two groups had no significant difference (P > 0. 05). Conclusion Compared with the single application of tiotropium, tiotropium plus sustained-release theophylline therapy can alleviate symptoms and improve life quality in patients with stable moderate COPD,without significantly increasing adverse reactions.
